Cartesian Therapeutics
Cartesian Therapeutics' revenue fell 92.8% to $3 million in fiscal 2025. Its operating margin was −5,127.1%, down from −112.8% a year earlier. Free cash flow was −$79 million. The diluted share count rose 49.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Cartesian Therapeutics lost money in fiscal 2025: a net loss of $130 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 128 | 135 | 77 | 213 | 125 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −1.6x | 4.8x | −30.5x | — | — |
| Current ratio | 2.0x | 5.9x | 1.3x | 9.4x | 8.7x |
| Quick ratio | 2.0x | 5.9x | 1.3x | 9.4x | 8.7x |
Cash flow
Projections
Project Cartesian Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $205,800 of Cartesian Therapeutics shares on the open market, and 3 insiders sold $258,683.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jan 6, 2026 | Carsten BrunnPresident and CEO, Director | Sold | 23,766 | $6.82 | $162,084 | Form 4 |
| Jan 6, 2026 | Blaine DavisChief Financial Officer | Sold | 10,591 | $6.82 | $72,231 | Form 4 |
| Jan 6, 2026 | Milos MiljkovicChief Medical Officer | Sold | 3,573 | $6.82 | $24,368 | Form 4 |
| Dec 4, 2025 | Timothy C BarabeDirector | Bought | 30,000 | $6.86 | $205,800 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −274.1% | −34.6% | −2,931.4% |
| Altman Z'' | −9.03 | −2.96 | −10.08 |
| Accruals ratio | −71.6% | −14.5% | −15.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Fail | Fail |
| F-score | — | — | — |
Compare
Put Cartesian Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Cartesian Therapeutics | FY25 | −92.8% | −5,127.1% | −2,838.6% | — | — | — | |
| Upstream Bio | FY25 | 20.4% | −5,618.8% | −4,675.5% | — | — | — | Compare |
| GeoVax Labs | FY25 | −37.1% | −869.3% | −863.8% | — | — | 2 | Compare |
| CAMP4 Therapeutics | FY25 | 436.5% | −1,502.4% | −852.8% | — | — | — | Compare |
| Marker Therapeutics | FY25 | −46.2% | −363.4% | — | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 8 | 0 | 1 | 7 | 17 | 85 | 111 | 26 | 39 | 3 |
| Revenue growth | 34.5% | −97.4% | 336.2% | 639.4% | 148.6% | 412.6% | 30.2% | −76.5% | 49.6% | −92.8% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 30 | 45 | 48 | 43 | 54 | 69 | 72 | 71 | 45 | 58 |
| Operating income | −35 | −64 | −65 | −52 | −57 | −5 | 14 | −86 | −44 | −143 |
| Net income | −36 | −65 | −65 | −55 | −69 | −26 | 35 | −220 | −77 | −130 |
| Diluted EPS (US$) | −116.70 | −96.00 | −87.60 | −36.60 | −20.40 | −6.60 | 3.00 | −49.76 | −4.49 | −5.02 |
| Diluted shares (millions) | 0 | 1 | 1 | 2 | 3 | 4 | 5 | 5 | 17 | 26 |
| Cash flow | ||||||||||
| Cash from operations | −20 | −52 | −59 | −51 | 35 | −60 | −32 | −51 | −24 | −74 |
| Capital expenditure | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 9 | 6 |
| Free cash flow | −20 | −53 | −60 | −51 | 34 | −61 | −33 | −51 | −33 | −79 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 4 | 6 | 5 | 5 | 8 | 11 | 22 | 7 | 10 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 84 | 97 | 37 | 90 | 139 | 128 | 135 | 77 | 213 | 125 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 89 | 101 | 44 | 100 | 165 | 160 | 166 | 305 | 435 | 296 |
| Total liabilities | 34 | 49 | 50 | 91 | 183 | 137 | 72 | 445 | 442 | 423 |
| Shareholders' equity | 55 | 52 | −5 | 8 | −18 | 22 | 94 | −440 | −7 | −126 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −428.9% | −30,813.5% | −7,200.7% | −785.6% | −342.4% | −5.4% | 13.1% | −332.3% | −112.8% | −5,127.1% |
| Net margin | −448.0% | −31,556.0% | −7,235.4% | −829.0% | −415.0% | −30.2% | 31.9% | −844.9% | −199.0% | −4,658.6% |
| Free cash flow margin | −251.7% | −25,487.4% | −6,649.5% | −771.0% | 205.2% | −72.2% | −29.6% | −197.5% | −84.2% | −2,838.6% |
| Rule of 40 (growth + FCF margin) | −217.2% | −25,584.9% | −6,313.3% | −131.6% | 353.8% | 340.4% | 0.6% | −274.1% | −34.6% | −2,931.4% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | −122.4% | −281.6% | — | — | — | 60.8% | — | — | — |
| Return on assets | −54.8% | −68.6% | −89.8% | −76.8% | −52.0% | −15.8% | 21.7% | −93.3% | −20.9% | −35.6% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |